ProfileGDS5678 / 1416296_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 84% 85% 96% 85% 85% 85% 85% 87% 85% 85% 88% 85% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3849385
GSM967853U87-EV human glioblastoma xenograft - Control 26.309884
GSM967854U87-EV human glioblastoma xenograft - Control 36.3847385
GSM967855U87-EV human glioblastoma xenograft - Control 49.0051696
GSM967856U87-EV human glioblastoma xenograft - Control 56.4553585
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2056285
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2766585
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.369485
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5855987
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3809485
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3755485
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9146688
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3835385
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3800885